Bio-Techne reports flat FY2026 revenue, EPS rise, and confirms $11.3B acquisition by Merck KGaA.

Bio-Techne Corporation reported flat revenue of $1.2 billion for fiscal year 2026, with a 3% organic revenue increase in Q4. GAAP EPS rose to $1.16 for the full year from $0.46 last year, while adjusted EPS slightly increased to $1.93. The company highlighted improved operating margins and profitability initiatives. Bio-Techne also confirmed its pending acquisition by Merck KGaA for $73 per share, valuing the deal at approximately $11.3 billion, signaling strategic growth opportunities ahead.